Human health risk assessment of pharmaceuticals in water: An uncertainty analysis for meprobamate, carbamazepine, and phenytoin

Regulatory Toxicology and Pharmacology

Volumn 57, Issue 2-3, 2010, Pages 146-156

  Kumar, Arun ^a   Xagoraraki, Irene ^a  

^a Michigan State University   (United States)

Author keywords

Human health; Pharmaceuticals; Risk assessment; Toxicity; Uncertainty

Indexed keywords

CARBAMAZEPINE; DRINKING WATER; MEPROBAMATE; PHENYTOIN;

ANALYTIC METHOD; ARTICLE; CONCENTRATION (PARAMETERS); ENVIRONMENTAL EXPOSURE; FLUID INTAKE; FOOD CONTAMINATION; FOOD INTAKE; HEALTH HAZARD; MONTE CARLO METHOD; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RISK ASSESSMENT; STANDARDIZATION; WATER CONTAMINATION;

ADOLESCENT; ADULT; AGED; ANIMALS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DRINKING; ENDPOINT DETERMINATION; ENVIRONMENTAL EXPOSURE; FISHES; FOOD CHAIN; HUMANS; INFANT; MEPROBAMATE; MIDDLE AGED; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PHENYTOIN; RISK ASSESSMENT; SEAFOOD; UNCERTAINTY; WATER POLLUTANTS, CHEMICAL; YOUNG ADULT;

EID: 77953356803     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.02.002     Document Type: Article

References (50)

1. Argall J.A.W., Wright N., Mackway-Jones K., Jackson R. A comparison of two commonly used methods of weight estimation. Arch. Dis. Child. 2003, 88:789-790.
2. Benotti M.J., Trenholm B.A., Vanderford B.J., Holady J.C., Stanford B.D., Snyder S.A. Pharmaceuticals and endocrine disrupting compounds in U.S. drinking water. Environ. Sci. Technol. 2009, 43:597-603.
3. Bercu J.P., Parke N.J., Fiori J.M., Meyerhoff R.D. Human health risk assessments for three neuropharmaceutical compounds in surface waters. Regul. Toxicol. Pharmacol. 2008, 50:420-427.
4. Chowdhury S., Champagne, Mc.Lellan P.J. Uncertainty characterization approaches for risk assessment of DBPs in drinking water: a review. J. Environ. Mgmt. 2009, 90:1680-1691.
5. Christensen F.M. Pharmaceuticals in the environment - a human risk?. Regul. Toxicol. Pharmacol. 1998, 28:212-221.
6. Cleuvers M. Mixture toxicity of the anti-inflammatory drugs diclofenac, ibuprofen, naproxen, and acetylsalicylic acid. Ecotoxicol. Environ. Saf. 2004, 59:309-315.
7. Cooper E.R., Siewicki T.C., Phillips K. Preliminary risk assessment database and risk ranking of pharmaceuticals in the environment. Sci. Tot. Environ. 2008, 398(1-3):26-33.
8. Cunningham V.L., Binks S.P., Olson M.J. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Regul. Toxicol. Pharmacol. 2009, 53:39-45.
9. Donovan E., Unice K., Roberts J.D., Harris M., Finley B. Risk of gastrointestinal disease associated with exposure to pathogens in the water of the Lower Passaic River. Appl. Environ. Microbiol. 2008, 74(4):994-1003.
10. Dufour A.P., Evans O., Behymer T.D., Cantu R. Water ingestion during swimming activities in a pool: a pilot study. J. Water Health 2006, 4:425-430.
11. Gurian P.L., Small M.J., Lockwood J.R., Schervish M.J. Benefit-cost implications of multicontaminant drinking water standards. J. Am. Water Works Assoc. 2004, 96(3):70-83.
12. Haas C.N., Rose J.B., Gerba C.P. Quantitative Microbial Risk Assessment 1999, John Wiley & Sons, Inc., New York, NY.
13. Hazardous substance data bank (HSDB), 2009. Available from: Accessed December 1, 2009. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB.
14. Hernandez-Diaz S., Werler M.M., Walker A.M., Mitchell Folic acid antagonists during pregnancy and the risk of birth defects. N. Engl. J. Med. 2000, 343(22):1608-1614.
15. Hernandez-Diaz S., Werler M.M., Walker A.M., Mitchell Neutral tube defects in relation to use of folic acid antagonists during pregnancy. Am. J. Epidemiol. 2001, 153(10):961-968.
16. Johnson A.C., Jurgens M.D., Williams R.J., Kummerer K., Kortenkamp A., Sumpter J.P. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J. Hydrol. 2008, 348:167-175.
17. Jones O.A., Lester J.N., Voulvoulis N. Pharmaceuticals: a threat to drinking water?. Trends Biotechnol. 2005, 23(4):163-167.
18. Kolpin D.W., Furlong E.T., Meyer M.T., Thurman E.M., Zaugg S.D., Barber L.B., Buxton H.T. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ. Sci. Technol. 2002, 36:1202-1211.
19. Kumar A., Adak P., Gurian P.L., Lockwood J.R. Arsenic exposure in U.S. public and domestic drinking water supplies: a comparative risk assessment. J. Expo. Sci. Environ. Epidemiol 2009, 1-10.
20. Meylan W.M., Howerd P.H., Boethling R.S., Aronson D., Printup H., Gouchie S. Improve method for estimating bioconcentration/bioaccumulation factor for octanol/water partition coefficient. Environ. Toxicol. Chem. 1999, 18:664-672.
21. Mitchell R.R., Summer C.L., Blonde S.A., Bush D.M., Hurlburt G.K., Snyder E.M., Giesy J.P. SCRAM: a scoring and ranking system for persistent, bioaccumulative, and toxic substances for the North American Great Lakes-resulting chemical scores and ranking. Hum. Ecol. Risk Assess. 2002, 8(3):537-557.
22. Morgan M.G., Henrion M. Uncertainty: a guide to Dealing with Uncertainty in Quantitative Risk and Policy Analysis 1995, Cambridge University Press, New York, NY.
23. Munoz I., Gomez M.J., Molina-Diaz A., Huijbregts M.A.J., Fernandez-Alba A.R., Garcia-Calvo E. Ranking potential impacts of priority and emerging pollutants in urban wastewater through life cycle impact assessment. Chemosphere 2008, 74:37-44.
24. National Toxicology Program (NTP) 2000. NTP technical report on the toxicity studies of Carisprodol (CAS No. 78-44-4) administered by gavage to f344/N rats and B6CF1 mice. Available from: . Accessed January 4, 2010. http://ntp.niehs.nih.gov/ntp/htdocs/ST_rpts/tox056.pdf.
25. Ohmori H., Yamashita K., Hatta T., Yamasaki S., Kawamura M., Higashi Y., Yata N., Yasuda M. Effects of low-dose phenytoin administered to newborn mice on developing cerebellum. Neurotoxicol. Teratol. 1997, 19(3):205-211.
26. Ott W.R. Environmental Statistics and Data Analysis 1995, CRC Press, Inc., Boca Raton, Fl.
27. Pomati F., Orlandi C., Clerici M., Luciani F., Zuccato E. Effects and interactions in an environmentally relevant mixture of pharmaceuticals. Toxicol. Sci. 2008, 102(1):129-137.
28. Rowney N.C., Johnson A.C., Williams R.J. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ. Toxicol. Chem. 2009, 28(12):2733-2743.
29. Sabourin L., Beck A., Duenik P.W., Kleywegt S., Lapen D.R., Li H., Metcalfe C.D., Payne M., Topp E. Runoff of pharmaceuticals and personal care products following application of dewatered municipal biosolids to an agricultural field. Sci. Total. Environ. 2009, 407:4596-4604.
30. Samren E.B., van Duijn C.M., Koch S., Hiilesmaa V.K., Klepel H., Bardy A.H., Mannagetta G.B., Deichl A.W., Gaily E., Granstrom M.L., Meinardi H., Grobbee D.E., Hofman A., Janz D., Lindhout D. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997, 38(9):981-990.
31. Samren E.B., van Duijn C.M., Christiaens G.C., Hofman A., Lindhout D. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann. Neurol. 1999, 46(5):739-746.
32. Sanderson H., Johnson D.J., Reitsma T., Brain R.A., Wilson C.J., Solomon K.R. Ranking and prioritization of environmental risks of pharmaceuticals in surface waters. Regul. Toxicol. Pharmacol. 2004, 39:158-183.
33. Schwab R.W., Hayes E.P., Fiori J.M., Mastrocco F.J., Roden N.M., Cragin D., Meyerhoff R.D., D'Aco V.J., Anderson P.D. Human pharmaceuticals in US surface waters: a human health risk assessment. Regul. Toxicol. Pharmacol. 2005, 42:296-312.
34. Schulman L.J., Sargent E.V., Naumann B.D., Faria E.C., Dolan D.G., Wargo J.P. A human health risk assessment of pharmaceuticals in the aquatic environment. Hum. Ecol. Risk assess 2002, 8(4):657-680.
35. SCR PhysProp Database., 2009. Interactive physProp database demo. Available from: . Accessed July 26, 2009. http://www.srcinc.com/what-we-do/databaseforms.aspx?id=386.
36. Silva E., Rajapakse N., Kortenkamp A. Something from " Nothing" - Eight weak estrogenic chemicals combined at concentrations below NOECs produce significant mixture effects. Environ. Sci. Technol. 2002, 36:1751-1756.
37. Snyder S.A., Wart E.C., Lei H.D., Westerhoff P., Yoon Y. Removal of EDCs and Pharmaceuticals in Drinking and Reuse Treatment Processes 2007, Awwa Research Foundation, USA.
38. Snyder S.A. Occurrence, treatment, and toxicological relevance of EDCs and pharmaceuticals in water. Ozone: Sci. Eng. 2008, 30:65-69.
39. Snyder S.A., Trenholm R.A., Snyder E.M., Bruce G.M., Pleus R.C., Hemming J.D.C. Toxicological Relevance of EDCs and Pharmaceuticals in Drinking Water 2008, Awwa Research Foundation, USA.
40. Snyder S.A., Vanderford B.J., Drewes J., Dickenson E., Snyder E.M., Bruce G.M., Pleus R.C. State of Knowledge of Endocrine Disruptors and Pharmaceuticals in Drinking Water 2008, Awwa Research Foundation, USA.
41. Stackelberg P.E., Furlong E.T., Myer M.T., Zuagg S.D., Henderon A.K., Reissman D.B. Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water-treatment plant. Sci. Tot. Environ. 2004, 329:99-113.
42. Stackelberg P.E., Gibs J., Furlong E.T., Meyer M.T., Zaugg S.D., Lippincott R.L. Efficiency of conventional drinking-water-treatment processes in removal of pharmaceuticals and other organic compounds. Sci. Total. Environ. 2007, 377:255-272.
43. United States Environmental Protection Agency (U.S. EPA), 1997. Exposure factors handbook. EPA/600/P-95/002Fa.
44. US EPA, 2006. Setting standards for safe drinking water. Available from: . Accessed December 2, 2009. http://www.epa.gov/ogwdw/standard/setting.html.
45. US EPA, 2009. Available from: . Accessed February 26, 2009. http://www.epa.gov/risk/health-risk.htm.
46. Voigt K., Bruggemann R. Ranking of pharmaceuticals detected in the environment: aggregation and weighting procedures. Comb. Chem. High Throughput Screen. 2008, 11:770-782.
47. Webb S., Ternes T., Gibert M., Olejniczak K. Indirect human exposure to pharmaceuticals via drinking water. Toxicol. Lett. 2003, 142:157-167.
48. Westerhoff P., Yoon Y., Shane S., Wert E. Fate of endocrine-disruptor, pharmaceutical, and personal care product chemicals during simulated drinking water treatment processes. Environ. Sci. Technol. 2005, 39:6649-6663.
49. Wong M., Kumar L., Jenkins T.M., Xagoraraki, Phanikumar M.S., Rose J.B. Evaluation of public health risks at recreational beaches in Lake Michigan via detection of enteric viruses and a human-specific bacteriological marker. Water Res. 2009, 43:1137-1149.
50. Xagoraraki I., Kuo D. Water pollution: emerging contaminants associated with drinking water. International Encyclopedia of Public Health 2008, 539-550. Academic Press, San Diego. K. Heggenhougen, S. Quah (Eds.).